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ing an additional unintended pregnancy with ulipristal acetate as compared to 
levonorgestrel is estimated to be 418€ . Ulipristal acetate is most cost-effective in 
the subgroup of intake within 24 hours, where it is more efficacious at a lower cost 
compared to levonorgestrel. ConClusions: Ulipristal acetate is a cost-effective 
alternative to levonorgestrel, given that the cost of avoiding an additional pregnancy 
with ulipristal acetate is less than the average cost of said pregnancies. Therefore, 
French minors should have free access to ulipristal acetate directly in a pharmacy. 
Ulipristal acetate should be used rapidly after unprotected intercourse (within 
24hours) to benefit from its cost-saving potential compared to levonorgestrel use.
PIH35
CervICal assessment WItH Progesterone In tHe PreventIon of 
Preterm BIrtH: a strategy Based on Cost-effeCtIveness
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inTRoDuCTion: Preterm birth (PTB) complications are estimated to be the second 
most common cause of death in under-five children and responsible for 3.1million 
neonatal deaths. According to a worldwide analysis, Brazil is one of the top ten 
countries with the highest number of PTB. Considering its long-term costs, strate-
gies that reduce incidence may be cost-effective. Treatment with progesterone is 
one of the interventions recommended for PTB prevention due to the evidence 
supporting its efficacy in women with short cervix and prior history of preterm 
delivery. objeCTives: Determine whether treatment with progesterone for preg-
nant women with a short cervical length < 25mm identified in routine measurement 
of second-trimester transvaginal cervical length by ultrasound in low-risk singleton 
pregnancies is a cost-effective strategy under the Brazilian Healthcare System per-
spective. MeThoDs: A cohort model was developed according to the disease and 
resources use. Epidemiology of pregnancies at risk of PTB eligible for progesterone 
treatment were obtained from published data. To obtain national clinical data, births 
were categorized by gestational week age at delivery specialist opinion. Progesterone 
effectiveness data were obtained from systematic reviews, meta-analysis and spe-
cialist opinion. Costs included screening test, prenatal consultation, progesterone 
and neonatal hospitalization. Exchange rate was 1USD= 2.30BRL. Results were pre-
sented in cost/PTB avoided. ResulTs: Considering 278.100 PTB, the inclusion of 
screening test to identify pregnant women with short cervix and its prophylaxis 
with progesterone shows significant economic savings of USD74 million. Although 
the expenditure on drug, screening test and prenatal consultation increment the 
total costs, the reduced number of PTB (263,052 vs 278.100) and neonatal UTI hos-
pitalization length (4,098,543 days vs 4,518,056 days) resulted in a total economic 
saving. ConClusions: Prevention of PTB is dominant in women with short cervix 
as compared to a no-prophylactic strategy scenario resulting in economic savings 
to the Brazilian health care system.
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Cost-effeCtIveness of PalIvIzumaB use In HIgH rIsk CHIldren from 
BrazIlIan HealtH system PersPeCtIve
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objeCTives: This study aimed to investigate the cost-effectiveness of palivizumab 
to different combinations of risk groups, such as premature children born with ges-
tational age (GA) ≤ 28 weeks, GA ≤ 32 weeks, children with congenital heart disease 
and bronchopulmonary dysplasia. MeThoDs: Literature review was performed to 
search effectiveness data. One Markov model (base case), and one decision tree 
(alternative scenario) were built with a cohort simulation along a 18 years-time 
horizon for the base case and a 1 year time horizon for the decision tree. Base case 
consider sequelae after infection, and alternative scenario not. The Health System 
perspective was used, with a discount rate of 5%. A probabilistic sensitivity analysis 
(Monte Carlo simulation) with probability distributions fitted to the variables, was 
performed under the different structural assumptions, as well as a deterministic 
analysis, using Tornado diagram, to verify the variable modifications able to alter 
the responses of the model. A threshold analysis was used to estimate the price 
that palivizumab would fit under an acceptability threshold proposed for the health 
system. ResulTs: The option of using the prophylaxis just in preterm children born 
with GA ≤ 32 weeks dominated all others. The incremental effectiveness of base 
case analysis compared with no prophylaxis (base line) was 0.19 QALY. However, 
this strategy was not cost-effective, presenting an incremental cost-effectiveness 
ratio (ICER) of R$ 81,627.31/QALY, value above of World Health Organization (WHO) 
proposed threshold of three times GDP per capita (R$ 63,756.00/QALY). The ICER of 
GA ≤ 32 weeks in alternative scenario was 2.023.045,72, showing the importance of 
considering sequelae in analysis. Sensitivity analysis showed that some variables 
when altered were able to change model final answers. ConClusions: Threshold 
analyses demonstrated that palivizumab price must be reduced in at least 22% to 
be incorporated to all populations use, based on WHO threshold.
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objeCTives: Children undergoing cardiac surgery for congenital heart disease are 
more likely to experience development of acute kidney injury (AKI) in the immedi-
ate postoperative period. In current clinical practice, AKI diagnosis is based on a 
rise in serum creatinine (sCr) levels, which occurs 2-3 days after the initiating renal 
insult. Many new biomarkers offer promise for earlier AKI diagnosis. The objective 
for RT intervention and US$ 17.88/DALY for RPR intervention. Cost-effectiveness 
ratios (CERs) were more sensitive to the prevalence rate, sensitivity of tests, and 
DALY discount rate. ConClusions: Using the on-site antenatal rapid testing, same 
day treatment for positive results, and confirmed by RPR testing approach is cost-
effective in Mongolia.
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objeCTives: To estimate the cost-effectiveness of the supply of calcium of 1200mg 
per day from the week 14 of pregnancy to all pregnant women compared to not 
supplying it to reduce the incidence of preeclampsia. MeThoDs: A decision tree 
was built in TreeAge® with outcome measured in life years gained (LYG) associated 
to the reduction in maternal deaths. The costs were included from the perspective 
of the Health System in Colombia. Pharmaceutical costs were obtained from 2008 
SISMED (1) and the value of the procedures was calculated by adjusting the values 
of Tariff Manual ISS 2001 + 30% (2), these values were compared with information 
of costs supplied by three EPS. All costs are expressed in Colombian pesos of 2010. 
The discount rate was 0%. It was performed sensitivity univariate and probabilistic 
analyzes for costs and effectiveness. ResulTs: Compared to no intervention, calcium 
supplement is a dominant alternative. If the incidence of preeclampsia is lower than 
51.7 per 1000 pregnant women or the cost per tablet of calcium of 600 mg is greater 
than $454, calcium supplement is no longer a cost-effective alternative in Colombia 
for a threshold of 3 times the GDP per capita in Colombia of 2010 by LYG, equal to 
$36,143,550. ConClusions: Supply of calcium to all pregnant women from week 
14 of gestation is a dominant alternative compared to no intervention, which saves 
200 LYG, while it decreases costs in the order of $5,304 million pesos per 100.000 
pregnant women.
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objeCTives: Ulipristal acetate is a selective progesterone receptor modulator 
that has been demonstrated to be an effective 3-month pre-operative treatment 
for moderate to severe symptoms of uterine fibroids in adult women of repro-
ductive age. The aim of this analysis was to assess the cost-effectiveness of 5 mg 
ulipristal acetate as an add-on therapy to standard pre-surgical observation and 
treatment or immediate hysterectomy in Romania. MeThoDs: A Markov model 
was developed using a 10-year time horizon. Ulipristal acetate was compared with 
pre-surgical observation and immediate hysterectomy. The model comprised the 
following mutually exclusive health states: mild, moderate, severe, or persistent 
severe excessive bleeding disorder; myomectomy; post-myomectomy with mildly to 
moderately excessive bleeding disorder; post-myomectomy with severely excessive 
bleeding disorder; hysterectomy; post-hysterectomy; post-menopause; and death. 
Transition probabilities and utility values were obtained from clinical trials and the 
scientific literature. Resource utilisation and unit costs were derived from the con-
sensus panel of clinical experts and the Romanian National Insurance House tariffs. 
Cost vectors in RON were converted to EUR by using 2013 Romanian National Bank 
average exchange rate (1 EUR = 4.419 RON). ResulTs: Adding a 3-month course of 
ulipristal acetate to pre-operative observation was predicted to achieve an addi-
tional 0.021 quality-adjusted life years (QALYs) at an estimated incremental cost of 
367 € , which would result in an incremental cost of 17,749 € /QALY. When 3 months 
of ulipristal acetate therapy was compared with immediate hysterectomy, the incre-
mental cost-effectiveness ratio was reduced to 2,300 € /QALY. The results were most 
sensitive to the utility value of the post-hysterectomy health state but responsive 
to changes in other model parameters. ConClusions: The results of this analysis 
suggest that adding ulipristal acetate treatment to standard pre-surgical therapy 
represents a good value for money in Romania. The inclusion of societal benefits 
may considerably reduce the cost-effectiveness ratio.
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WItH ulIPrIstal aCetate versus levonorgestrel for mInors In 
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Schmid R.
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objeCTives: To compare the cost and effectiveness of two emergency contracep-
tive methods in minors in France and to support the payer’s analysis if it is worth 
to deliver ulipristal acetate for free to minors. MeThoDs: Based on a decision-
analytical model, the cost-effectiveness of two emergency contraceptive meth-
ods is compared. Pregnancy rates, outcome of unintended pregnancy in minors 
and resource utilization are derived from literature. Resources and their costs are 
considered until termination or a few days after delivery. Costs are taken from a col-
lective perspective. Sensitivity analyses are performed on the most sensitive input 
parameters. ResulTs: Using emergency contraception is superior to no method. 
The cost of an unintended pregnancy in a French minor is estimated to be 1630€ 
(1330€ - 1803€ ). Almost 4 million€ (3.1-13.7million€ ) could have been saved by using 
ulipristal acetate instead of levonorgestrel in 2010. The incremental cost of avoid-
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mize selection bias. Patients in both groups were required to be at least age 18 years, 
with continuous medical and pharmacy benefits 1 year before, and 1 year after the 
index date. One-to-one propensity score matching (PSM) was used to compare health 
care costs and utilizations during the follow-up period between the menopausal and 
the comparison groups, and were adjusted for baseline demographic and clinical 
characteristics. ResulTs: After risk adjustment by PSM, a total of 67,740 patients 
in each cohort were matched. More menopausal patients had inpatient admissions 
(15.18% vs. 11.89%, p< 0.0001) and other service (99.98% vs. 90.29%, p< 0.0001) and 
pharmacy visits (86.55% vs. 71.23%, p< 0.0001) compared to those without menopause. 
Menopausal patients also incurred significantly higher other service visit ($11,215 vs. 
$8,812, p< 0.0001) and pharmacy costs ($2,448 vs. $1,878, p< 0.0001) than comparison 
patients. ConClusions: In the U.S. Medicaid program, menopausal patients had 
higher health care utilization and incurred higher costs than those without meno-
pause, highlighting the economic burden of the disease.
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objeCTives: Infantile Hemangioma (IH) is one of the most common childhood 
benign tumours. Recent studies have demonstrated the success of propranolol for 
involution of IH and the higher clinically effective and safe compared with corti-
costeroids. The purpose of this study is to estimate the cost-utility of propranolol, 
a new medicinal product authorized for this specific paediatric indication (3.75 mg/
mL, oral solution) versus corticosteroids (5.00 mg, tablets), used in clinical practice 
in absence of other authorised therapies of proliferating IH requiring systemic treat-
ment. MeThoDs: A life-time (30 years) mixed decision tree and Markov model 
has been developed to describe the pathway of infants with IH and to assess costs 
and outcomes (Quality-Adjusted Life Years – QALYs – gained) from the perspec-
tive of the Italian National Health Service (INHS). Clinical inputs derive from the 
manufacturer’s pivotal trial and literature review, validated by key clinicians in Italy. 
The economic evaluation considers direct medical costs associated with IH (drug 
acquisition, hospital admissions and outpatient visits) derived from public sources. 
The atopic dermatitis as a proxy for IH utilities, the Infants Dermatitis Quality of 
Life Index and the Children’s Dermatology Life Quality Index were used to estimate 
quality of life. Probabilistic sensitivity analyses (PSA) were performed to investigate 
model parameter uncertainties. Costs and health benefits have been discounted at 
an annual rate of 3.00%. ResulTs: The cumulative costs are € 2,399.32 and € 1,859.68 
while cumulative QALYs are 19.11 and 18.95 for propranolol and for corticoster-
oids respectively, corresponding to an ICUR of € 3,372.75/QALY. PSA results suggest 
that 94.60% of the 1000 iterations fall within a € 30,000 cost-effectiveness threshold 
considered acceptable for a marginal unit of effectiveness. ConClusions: The 
propranolol (3.75 mg/mL, oral solution for paediatric use) for the treatment of pro-
liferating IH can be considered cost-effective compared to corstisteroids (5.00 mg, 
tablets) in the INHS perspective.
PIH42
Cost effeCtIveness analysIs of a vaCCIne to Prevent HerPes zoster 
and PostHerPetIC neuralgIa In Italy
Coretti S., Ruggeri M., Codella P.
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objeCTives: The aim of this study was to assess the cost-effectiveness of HZ vac-
cination compared to no vaccination strategy which only involves the treatment of 
patients affected by HZ, within the Italian context. MeThoDs: The natural history 
of HZ and PHN was mapped through a Markov model with lifetime horizon and 
cycles lasting one month. Both third party payer (the Italian National Health Service) 
and societal perspectives were adopted. Costs and Effectiveness data was derived 
from literature and discounted by 3.5%. Model results are expressed in terms of 
incremental cost-effectiveness ratio (ICER). Both deterministic and probabilistic 
sensitivity analyses were performed to appraise the effect of parameters’ variation 
on model results. ResulTs: A population of patients with HZ aged between 60 and 
79 years was hypothesized. The ICER of the vaccination equaled € 12,155 per QALY 
under the NHS perspective and € 11,118 per QALY under the societal perspective. 
Moreover, under NHS perspective the cost per HZ-episode avoided and the cost per 
PHN-episode avoided amounted to € 1,098 and € 8,742 respectively. Considering a 
cost-effectiveness threshold of € 30,000/QALY, the probabilistic sensitivity analysis 
showed that vaccination is cost-effective regardless of the perspective adopted, in 
99% of simulations. ConClusions: Results showed that a vaccination program 
against herpes zoster and post-herpetic neuralgia is cost-effective in Italian patients 
aged between 60 and 79 years.
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objeCTives: The objective of this study was to estimate the incremental cost-
effectiveness ratio (ICER) of a medication review with follow-up (MRF) service for 
older people with polypharmacy in community pharmacies against the alternative 
of receiving usual dispensing. MeThoDs: The study was designed as a longitudi-
nal cluster randomized trial carried out over six months of follow-up. The target 
was to assess the incremental cost effectiveness of using serum CysC (sCysC), urine 
NGAL (uNGAL) and urine L-FABP (uL-FABP) for the diagnosis of AKI in children 
after cardiac surgery compared with current diagnostic method (monitoring of sCr 
level). MeThoDs: We developed a decision analytical model to estimate quality-
adjusted life years (QALY), lifetime costs and incremental cost-effectiveness of dif-
ferent biomarker-based diagnostic strategies which can be used in clinical practice 
compared to current strategy. This model simulates detection of AKI, its progression 
to chronic kidney disease (CKD) and CKD treatment in cohort of patients younger 
than 18 years. ResulTs: The cost-effectiveness ratios were between $1485/QALY for 
sCr and $3579/QALY for uNGAL. uNGAL and sCys C strategies yielded higher costs 
and lower effectiveness (ie. dominated) compared to uL-FABP strategy. uL-FABP 
added 1.43 QALY compared to current diagnostic method at an additional cost of 
$8521.87. ICER for uL-FABP compared to sCr was $5959.35/QALY. Probabilistic sensi-
tivity analyses indicated that the uL-FABP strategy was cost-effective for all 10.000 
patient simulations at specified $50000/QALY threshold. ConClusions: Our results 
suggest that the use of uL-FABP is likely to represent an economically advantageous 
strategy for early AKI diagnosis in children after cardiac surgery. However, we need 
rapid screening uL-FABP test to ensure timely and efficient AKI treatment.
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objeCTives: Endometriosis is a disease with social and economic impact. We anal-
yses the clinical and pharmaco-economical efficacy of the treatment of genital 
endometriosis. MeThoDs: This open-label prospective comparative research was 
performed in 2012-2013 on Center of Endometriosis of Astana. Results of treat-
ment taken from 180 female patients with endometriosis aged 19-35 years old were 
included into the study. All of them were divided on three groups depending on the 
methods of therapy. 1st group have a endo-surgery treatment (60 patient), 2nd group 
(60 patient) - only hormonal therapy (Dienogest 2 mg per day for 6 months) and 3rd 
group - combined therapy (after endo-surgery taken the Dienogest 2 mg per day 
for 6 months). For the calculation of cost/effectiveness index we included all of the 
direct medical expenses. ResulTs: In the first group efficacy index is 66,7%, in the 
second group – 70,0% and in the third group – 91,7%. Index cost/effectiveness for 
endo-surgery is 143 298 KT (1$= 182KT), cost/effectiveness for hormonal therapy 
is 92 428 KT and cost/effectiveness for combined methods is 115 718 KT. Surgical 
treatment has the low efficiency of the high costs compared with other therapies. 
The indicator of cost/effectiveness of the combined therapy is higher than in the 
hormonal treatment: higher efficiency cost in additional costs. For the objectifica-
tion of this fact calculated Incremental Index per patient: 186 500 - 107 833 / 92.0 
- 70.0 = 182 KT. So, the increase of one percent of effectiveness combined therapy 
compare to hormonal therapy reflects additional cost, not more than 182 KT per 
patient. ConClusions: Hormonal therapy resulted as the cost-saving therapy of 
genital endometriosis in young women. The higher efficiency of treatment of endo-
metriosis are needed additional expenses.
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objeCTives: Most elderly prefer to grow old in the community within a famil-
iar environment, instead of moving to a nursing home. Preventive home visits 
based on multidimensional geriatric assessment can be one strategy to support 
this preference and might additionally reduce health care costs, due to the avoid-
ance of costly nursing home admissions. The purpose of this study was to ana-
lyse the cost-effectiveness of preventive home visits from a societal perspective in 
Germany. MeThoDs: This study is part of a multi-centre, non-blinded, randomised 
controlled trial. Participants were older than 80 years and living at home. Three 
home visits were conducted to identify self-care deficits and risk factors, to pre-
sent recommendations and to implement solutions. The control group received 
usual care. A cost-utility analysis using QALY based on the EQ-5D was performed. 
A cost-effectiveness acceptability curve controlled for confounding variables was 
constructed. A sensitivity analysis to control for the influence of the mode of QALY 
calculation was performed. ResulTs: 278 individuals were included in the analy-
sis. Mean total cost (+874 EUR) and number of QALY (+0.0014) were higher in the 
usual care group, but differences were not significant. The probability for cost-
effectiveness of preventive home visits increased from 6% (Willingness-to-pay: 
0 € / QALY) 30% (Willingness-to-pay: 250.000 € / QALY). The results were robust to 
the mode of QALY calculation. The probability of cost-effectiveness did not exceed 
30%. ConClusions: We found convincing evidence that the evaluated preventive 
home visits programme is not cost-effective.
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objeCTives: To evaluate the economic burden of menopausal women enrolled in the 
U.S. Medicaid program. MeThoDs: Menopausal women (International Classification 
of Disease, 9thRevision, Clinical Modification [ICD-9-CM] diagnosis code 627) were 
identified using U.S. Medicaid data from 01JAN2008 through 31DEC2010. The initial 
diagnosis date was designated as the index date. A separate group of patients without 
a menopause diagnosis but of the same age, race, and gender was identified, matched 
and designated as the comparison group. A random index date was chosen to mini-
